• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

分泌型白细胞蛋白酶抑制剂在口腔白斑病和口腔鳞状细胞癌中的表达及凋亡作用。

Secretory leukocyte peptidase inhibitor expression and apoptosis effect in oral leukoplakia and oral squamous cell carcinoma.

机构信息

Department of General Dentistry, The Ninth People's Hospital Affiliated to Shanghai JiaoTong University School of Medicine, Shanghai 200000, P.R. China.

Department of Stomatology, Tai'an Central Hospital, Tai'an, Shandong 271000, P.R. China.

出版信息

Oncol Rep. 2018 Apr;39(4):1793-1804. doi: 10.3892/or.2018.6251. Epub 2018 Feb 7.

DOI:10.3892/or.2018.6251
PMID:29436667
Abstract

Oral leukoplakia (OL) is one of the most common oral precancerous lesions with the possibility of malignant transformation, ranging from 17 to 24% of patients with a median follow-up of >7 years. Previous research has revealed that compared with normal oral epithelial tissues, the expression of secretory leukocyte peptidase inhibitor (SLPI) protein is significantly reduced in oral squamous cell carcinoma (OSCC). Based on the above-mentioned research, it is known that SLPI is a potential predictive and diagnostic tool for the progression of oral carcinogenesis. Therefore, we investigated the correlation between the abundance of SLPI protein and the different histological grades of OL by immunohistochemistry. The results indicated that the level of SLPI was negatively correlated with the histological grades of the oral premalignant lesions, indicating that it may be a potential predictive tool for the malignant transformation presented in oral precancerous patients. Subsequently, we investigated the biological effects of SLPI using Cell Counting Kit (CCK)-8, Annexin V/PI apoptosis assay and Caspase-Glo® 3/7 assay. The findings revealed that SLPI promoted apoptosis in the Leuk1 and WSU-HN4 cell lines. Mechanistic studies indicated that SLPI, at least in part, regulated cell apoptosis by inhibiting the expression of TNF receptor-associated factor 1 (TRAF1), which has a close relationship with the nuclear factor-κB (NF-κB) pathway.

摘要

口腔白斑病(OL)是最常见的口腔癌前病变之一,有 17%至 24%的患者存在恶性转化的可能,中位随访时间>7 年。先前的研究表明,与正常口腔上皮组织相比,口腔鳞状细胞癌(OSCC)中分泌白细胞蛋白酶抑制剂(SLPI)蛋白的表达显著降低。基于上述研究,已知 SLPI 是口腔癌发生进展的潜在预测和诊断工具。因此,我们通过免疫组织化学研究了 SLPI 蛋白丰度与 OL 不同组织学分级之间的相关性。结果表明,SLPI 水平与口腔癌前病变的组织学分级呈负相关,表明其可能是口腔癌前患者恶性转化的潜在预测工具。随后,我们使用细胞计数试剂盒(CCK)-8、Annexin V/PI 凋亡测定和 Caspase-Glo®3/7 测定研究了 SLPI 的生物学效应。结果表明,SLPI 促进了 Leuk1 和 WSU-HN4 细胞系的凋亡。机制研究表明,SLPI 至少部分通过抑制肿瘤坏死因子受体相关因子 1(TRAF1)的表达来调节细胞凋亡,而 TRAF1 与核因子-κB(NF-κB)途径密切相关。

相似文献

1
Secretory leukocyte peptidase inhibitor expression and apoptosis effect in oral leukoplakia and oral squamous cell carcinoma.分泌型白细胞蛋白酶抑制剂在口腔白斑病和口腔鳞状细胞癌中的表达及凋亡作用。
Oncol Rep. 2018 Apr;39(4):1793-1804. doi: 10.3892/or.2018.6251. Epub 2018 Feb 7.
2
Secretory leukocyte protease inhibitor (SLPI) expression and tumor invasion in oral squamous cell carcinoma.分泌白细胞蛋白酶抑制剂 (SLPI) 在口腔鳞状细胞癌中的表达与肿瘤侵袭。
Am J Pathol. 2011 Jun;178(6):2866-78. doi: 10.1016/j.ajpath.2011.02.017.
3
Detection of survivin and p53 in human oral cancer: correlation with clinicopathologic findings.人口腔癌中生存素和p53的检测:与临床病理结果的相关性
Head Neck. 2009 Aug;31(8):1039-48. doi: 10.1002/hed.21071.
4
Nodal metastasis and survival in oral cancer: Association with protein expression of SLPI, not with LCN2, TACSTD2, or THBS2.口腔癌中的淋巴结转移与生存:与分泌性白细胞蛋白酶抑制因子(SLPI)的蛋白表达相关,而非与中性粒细胞明胶酶相关脂质运载蛋白(LCN2)、肿瘤相关钙信号转导蛋白2(TACSTD2)或血小板反应蛋白2(THBS2)相关。
Head Neck. 2015 Aug;37(8):1130-6. doi: 10.1002/hed.23716. Epub 2014 Jul 19.
5
The methylation status and expression of human telomerase reverse transcriptase is significantly high in oral carcinogenesis.人端粒酶逆转录酶的甲基化状态和表达在口腔癌发生过程中显著升高。
APMIS. 2017 Sep;125(9):797-807. doi: 10.1111/apm.12723. Epub 2017 Aug 2.
6
Involvement of potential pathways in malignant transformation from oral leukoplakia to oral squamous cell carcinoma revealed by proteomic analysis.蛋白质组学分析揭示口腔白斑向口腔鳞状细胞癌恶性转化中潜在通路的参与情况。
BMC Genomics. 2009 Aug 19;10:383. doi: 10.1186/1471-2164-10-383.
7
Quantitative proteomic analysis of oral brush biopsies identifies secretory leukocyte protease inhibitor as a promising, mechanism-based oral cancer biomarker.口腔刷检活检的定量蛋白质组学分析确定分泌型白细胞蛋白酶抑制剂是一种有前景的、基于机制的口腔癌生物标志物。
PLoS One. 2014 Apr 18;9(4):e95389. doi: 10.1371/journal.pone.0095389. eCollection 2014.
8
Overexpression of immunomodulatory mediators in oral precancerous lesions.口腔癌前病变中免疫调节介质的过表达。
Hum Immunol. 2017 Nov;78(11-12):752-757. doi: 10.1016/j.humimm.2017.09.003. Epub 2017 Sep 21.
9
Interleukin-37 expression and its potential role in oral leukoplakia and oral squamous cell carcinoma.白细胞介素-37在口腔白斑和口腔鳞状细胞癌中的表达及其潜在作用。
Sci Rep. 2016 May 26;6:26757. doi: 10.1038/srep26757.
10
Transglutaminase 3 contributes to malignant transformation of oral leukoplakia to cancer.转谷氨酰胺酶 3 促进口腔白斑恶变为癌症。
Int J Biochem Cell Biol. 2018 Nov;104:34-42. doi: 10.1016/j.biocel.2018.08.016. Epub 2018 Aug 30.

引用本文的文献

1
Secretory leukocyte protease inhibitor as a novel predictive biomarker in patients with diabetic kidney disease.分泌型白细胞蛋白酶抑制剂作为糖尿病肾病患者的新型预测生物标志物。
Front Endocrinol (Lausanne). 2024 Mar 4;15:1334418. doi: 10.3389/fendo.2024.1334418. eCollection 2024.
2
The secretory leukocyte protease inhibitor (SLPI) in pathophysiology of non-communicable diseases: Evidence from experimental studies to clinical applications.分泌型白细胞蛋白酶抑制剂(SLPI)在非传染性疾病病理生理学中的作用:从实验研究到临床应用的证据
Heliyon. 2024 Jan 17;10(2):e24550. doi: 10.1016/j.heliyon.2024.e24550. eCollection 2024 Jan 30.
3
Up-regulation of secretory leukocyte protease inhibitor in human samples might have a potential role of predicting prostate cancer recurrence and progression after surgery and hormonal therapy.
在手术后和激素治疗后,人样本中分泌白细胞蛋白酶抑制剂的上调可能具有预测前列腺癌复发和进展的潜在作用。
Cancer Med. 2023 Feb;12(3):3328-3342. doi: 10.1002/cam4.5134. Epub 2022 Aug 13.
4
High expression of secretory leukocyte protease inhibitor (SLPI) in stage III micro-satellite stable colorectal cancer is associated with reduced disease recurrence.SLPI 在 III 期微卫星稳定结直肠癌中高表达与降低疾病复发相关。
Sci Rep. 2022 Jul 16;12(1):12174. doi: 10.1038/s41598-022-16427-5.
5
Anti-Protease Activity Deficient Secretory Leukocyte Protease Inhibitor (SLPI) Exerts Cardioprotective Effect against Myocardial Ischaemia/Reperfusion.抗蛋白酶活性缺陷的分泌型白细胞蛋白酶抑制剂(SLPI)对心肌缺血/再灌注具有心脏保护作用。
Biomedicines. 2022 Apr 25;10(5):988. doi: 10.3390/biomedicines10050988.
6
The Inhibition of Inflammatory Signaling Pathway by Secretory Leukocyte Protease Inhibitor can Improve Spinal Cord Injury.分泌白细胞蛋白酶抑制剂抑制炎症信号通路可改善脊髓损伤。
Cell Mol Neurobiol. 2020 Oct;40(7):1067-1073. doi: 10.1007/s10571-020-00799-1. Epub 2020 Jan 28.
7
Secretory leukocyte protease inhibitor suppresses HPV E6-expressing HNSCC progression by mediating NF-κB and Akt pathways.分泌型白细胞蛋白酶抑制剂通过介导NF-κB和Akt信号通路抑制表达人乳头瘤病毒E6的头颈部鳞状细胞癌进展。
Cancer Cell Int. 2019 Aug 23;19:220. doi: 10.1186/s12935-019-0942-7. eCollection 2019.